Sponsored Content
Massive Losses for Intercell
Sponsored Content
The Austrian pharmaceutical company today reported losses for 2010 amounting to € 255m. Operating cash flow has been strongly negative too.

Today Intercell AG (VSE: ICLL) announced its financial results for Q4 and the preliminary results for the full financial year 2010 and presented an update on the Company’s development programs.
In 2010, Intercell experienced a serious backdrop in its development. Due to a cancelled program for the development of vaccines, the company had to…
or Log In
Sponsored Content
Sponsored Content
Sponsored Content
Fast News Search
Related News
Intercell Issues Convertible Bond (February 23, 2011)
Intercell Raises Authorized Capital (December 16, 2010)
Serious setback for Intercell (December 14, 2010)
Economic Chamber in Tokyo: Biotechnology as an Opportunity (December 6, 2010)
Intercell AG: Losses Doubled, Positive Outlook (November 9, 2010)
Sponsored Content
Read More
Featured